Tuesday December 17, 2019
ISCT Leaders Featured in the Medicine Maker 2019 Cell and Gene Therapy
The Medicine Maker Cell and Gene Therapy Supplement "Next Level Cell and Gene Therapy" features interviews with ISCT leaders, Emily Hopewell, Karen Nichols, Patrick Rivers, and Bruce Levine, on key considerations for the CGT sector, including the talent gap, GMP, regulatory and investment landscape. Click here to read the supplement
Monday, November 18, 2019
ISCT PTF tackling borderless issue of unproven cell banking
BioProcess International article features PTF efforts to address unproven cell banking.
Monday, October 21, 2019
ISCT Statement of Concern Regarding Speculative Commercial Cell Banking Services
The International Society for Cell & Gene Therapy (ISCT), in conjunction with the undersigned partner professional and educational societies in the field of Cell and Gene Therapy, express a strong concern with the recent growth of speculative cell banking services that prey upon people’s fears while offering little, if any, prospect of medical benefit. Commercial cell banking services – including the banking of T-cells, dental cells and cells for the derivation of induced pluripotent stem cells for potential therapeutic uses, for example, are not supported by current scientific evidence. Without a clearer pathway to legitimate clinical use, offering these services commercially to patients is premature, misleading, and drives false hope. Read More.
Monday September 16, 2019
ISCT MSC Committee offers position statement on nomenclature of mesenchymal stromal cells
The ISCT MSC committee offers a position statement to clarify the nomenclature of mesenchymal stromal cells (MSCs). This position paper aims to build upon the committee's 2005 position statement, to further consolidate and clarify the ISCT position on functional definitions of mesenchymal stem versus stromal cells.
To Read the ISCT MSC committee position statement on nomenclature CLICK HERE!
Friday September 6, 2019
ISCT commends Google for prioritizing patient health by banning advertising for unproven CGTs
ISCT commends Google for prioritizing patient health and wellbeing by banning advertising for unproven cell and gene therapies. Read more here.
Wednesday July 10, 2019
2019 Commercialization Signature Series Meeting Report Now Available
For the third annual ISCT Commercialization Signature Series, ISCT Patron and Partner member companies gathered in Miami in January for discussion on the theme of ‘Patients First: Achieving Global CGT Adoption’.
The team at Cell & Gene Therapy Insights captured all the meeting highlights including keynote speaker Reni Benjamin (Raymond James), session 1 speakers Dan Shoemaker (Fate Therapeutics), Luca Alberici (MolMed), Amy DuRoss (Vineti) and Simon Ellison (World Courier) who discussed challenges in getting the product to the patient, followed by Gerhard Bauer (UC Davis), Richard Maziarz (Oregon Health & Science University), Mehrdad Abedi (UC Davis) and Peter Olagunju (bluebird bio) on strategies to overcoming adoption barriers. Read more.
Friday June 14, 2019
ISCT NA LRA Releases Two Publications on the State of FDA and HC Regulation for CGT Products
A major hurdle for worldwide development of Cellular & Gene Therapy Products (CGT) is the differing regulatory structures within various geographic jurisdictions. These differences impact patient access to innovative, potentially revolutionary and curative medical therapies. The International Society for Cell & Gene Therapy (ISCT) intends to contribute to the improving development and regulatory approval of CGTs in all areas of the globe. The first and second reviews in this potential global series is authored by the ISCT North America Legal & Regulatory Affairs (NA LRA) Committee and focuses specifically on the U.S and Canada. It is currently available in CytotherapyTM online and will be printed in the July issue. Access the publications and read more.
Access the ISCT News Archive